To the full analysis
Medical Properties Trust stock: growth
MPTMedical Properties Trust reported $972.02M in revenue for fiscal 2025, down 2.4% on the prior year, down 4.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.8%
per year from 2006 to 2025, per share 1.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −4.9% | 8.2% | 16.8% |
| Revenue per share | −7.3% | −2.2% | 1.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $50.47M | $30.16M | −$193.69M |
| 2007 | $81.79M | $41.24M | −$176.15M |
| 2008 | $107.07M | $32.7M | −$360.79M |
| 2009 | $114.04M | $36.33M | $62.33M |
| 2010 | $108.02M | $22.91M | −$83.81M |
| 2011 | $132.32M | $26.54M | −$190.24M |
| 2012 | $198.13M | $89.9M | $105.31M |
| 2013 | $242.52M | $96.99M | $140.8M |
| 2014 | $312.53M | $50.52M | $150.44M |
| 2015 | $441.88M | $139.6M | −$2.01B |
| 2016 | $541.14M | $225.05M | $292.24M |
| 2017 | $704.75M | $289.79M | −$1.88B |
| 2018 | $784.52M | $1.02B | −$981.91M |
| 2019 | $870.25M | $374.68M | −$4.36B |
| 2020 | $1.25B | $431.45M | −$3.67B |
| 2021 | $1.54B | $656.02M | $746.11M |
| 2022 | $1.54B | $902.6M | −$801.35M |
| 2023 | $871.8M | −$556.48M | $505.79M |
| 2024 | $995.55M | −$2.41B | $245.48M |
| 2025 | $972.02M | −$277.05M | $230.77M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.